E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Mild to moderate Alzheimer Disease |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 6.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012271 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the activity of AVE1625 at the doses of 10 and 40 mg/day in comparison to placebo in patients with mild to moderate Alzheimer Disease - Safety and tolerability by monitoring of adverse events, clinical laboratories, and ECG - Efficacy by evaluation of cognitive, global, and behavioral parameters |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the pharmacokinetic parameters of AVE1625 in patients with mild to moderate Alzheimer Disease |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1- The diagnosis of AD based on the DAT DSM-IV criteria and the INCDS/ADRDA criteria for Probable AD. 2- The diagnosis should also be supported by a Modified Hachinski score 4 and a CT scan/MRI of the brain performed within 12 months prior to randomization that is consistent with the diagnosis of AD. If a patient is followed at the investigational center, had a previous CT scan / MRI scan older than 12 months and has had no focal clinical changes then no new imaging is necessary. 3- Mild to moderate range of severity established by a Mini-Mental State Examination MMSE score 12 e 26 at screening |
|
E.4 | Principal exclusion criteria |
1. 50 years of age 2. Severe or unstable cardiovascular, respiratory, renal, hepatic, hematological, endocrinological, neurological or other somatic disease evidenced by history, physical examination, ECG or laboratory tests, which may interfere with the study in the investigator s judgment through interference with the evaluation of the study drug or with the absorption, metabolism or excretion of the study medication . In addition to those abnormalities which in the investigator s judgment are severe or unstable, the following alterations of laboratory tests / ECG findings on the screening must lead to exclusion of the patients a ALT or AST five times the upper limits of the reference range; b serum creatinine 150 mol / L; c neutrophils 1,500/mm3 , and d QTc 500 ms. 3. Evidence of any other primary central nervous system condition such as but not limited to Parkinson s disease, Multi-infarct dementia, or other dementias 4. Epilepsy 5. Current symptoms of depression at screening, patients on therapy, if stable for at least 3 months before randomization, with no significant symptoms, are allowed to be included . 6. Evidence of other primary psychiatric condition, which may interfere with the study in the investigator s judgment 7. Females of childbearing potential. Females of child bearing potential are defined as females who have experienced menarche and who have not undergone successful surgical sterilization hysterectomy, bilateral tubal ligation, bilateral oopherectomy or are not postmenopausal 8. Potent CYP3A4 inhibitors ritonavir, itraconaxole, nefazodone, ketoconazole, clarithromycin, telithromycin, troleandomycin, chloramphenicol, cyclosporine, grapefruit juice . 9. Potent CYP2C19 inhibitors fluvoxamine and fluconazole. 10. Use of CYP2C9 substrates sulfonylureas, glitazones, nateglinide, warfarin, losartan, irbesartan, fluvastatin, amytriptiline, fluoxetine, phenytoin, tamoxifen, leflunomid, acenocoumarol, phenprocoumon, hexobarbital, celecoxib 11. Patients with any of the following history or presence of blood dyscrasia and bleeding disorder including thrombocytopenia, thrombopathy, hypofibrinogenemia, hemophilia, anemia or known protein S or C deficiency; active or recent within 3 months of randomization significant bleeding, including gastrointestinal bleeding or peptic ulcer; laboratory coagulation parameters out of normal ranges INR 1.2 ; or use of anticoagulants or recent treatment with thrombolytic agents 12. Treatment with memantine 13. If treated with a cholinesterase inhibitor any change in therapy or dose in the 3 months prior to randomization 14. If previously treated with an approved theraphy for AD, but not currently treated, any change in therapy in the previous 3 months prior to randomization 15. Recent changes in treatment with atypical antipsychotics such as clozapine, olanzapine, risperidone, ziprasidone or expectations of changes during the duration of the study. In general these treatments should have been in use and well tolerated for 3 months prior to randomization with no change in dose in the 3 months prior to randomization. 16. Treatment with typical antipsychotics, tricyclic antidepressants or MAOI antidepressants. If previously administered, the patient should have stopped taking these drugs at least 4 weeks prior to randomization. 17. Participation in another clinical trial with an investigational drug or other investigational intervention within two months prior to randomization or with an investigational drug with a pharmacokinetic profile that would lead to the possibility that the drug was not fully eliminated 18. Inpatient in a total care facility e.g. Nursing home 19. Lack of reliable caregiver; who has contact with the patient at least 4 hours per day for 4 days per week or 2 hours per day for 7 days per week 20. Refusal or inability to give informed consent to participate in the study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety and tolerability Safety variables include the percentage of patients withdrawn from study drug due to an adverse event, reported adverse events, clinical laboratory values, ECG, neurological evaluation, and vital signs. Adverse events will be collected by spontaneous report, physical examination and neurological assessment, vital sign monitoring, clinical laboratories, and ECG s |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 12 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 12 |